Compare
Corvus Pharmaceuticals, Inc. vs Werewolf Therapeutics, Inc. vs Context Therapeutics Inc. vs Inovio Pharmaceuticals, Inc.
| Latest fiscal year | Corvus Pharmaceuticals, Inc. CRVS | Werewolf Therapeutics, Inc. HOWL | Context Therapeutics Inc. CNTX | Inovio Pharmaceuticals, Inc. INO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $65.3K |
| Revenue growth (YoY) | n/a | n/a | n/a | -70.0% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/m |
| Net margin | n/a | n/a | n/a | n/m |
| Net income | -$15.28M | -$60.82M | -$36.12M | -$84.95M |
| EPS (Diluted) | -$0.53 | -$1.33 | -$0.38 | -$1.81 |
| Operating cash flow | -$32.80M | -$60.29M | -$26.39M | -$88.63M |
| Free cash flow | -$32.97M | -$60.29M | -$26.42M | -$88.92M |
| Cash & equivalents | $4.58M | $57.05M | $66.00M | $44.27M |
| Total assets | $71.12M | $69.40M | $68.49M | $74.31M |
| Total liabilities | $9.91M | $44.59M | $8.02M | $50.21M |
| Shareholders' equity | $61.20M | $24.80M | $60.47M | $24.10M |
| Return on year-end equity | -25.0% | -245.2% | -59.7% | -352.5% |
| Shares outstanding | 74.70M | 48.60M | 91.88M | 69.00M |
Revenue, most recent five fiscal years
| Fiscal year | Corvus Pharmaceuticals, Inc. | Werewolf Therapeutics, Inc. | Context Therapeutics Inc. | Inovio Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | n/a | $65.3K Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | n/a | $217.8K Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | n/a | $832.0K Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | $10.26M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $1.77M Ended 2021-12-31 |